Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOTIS 6: loncastuximab tesirine versus idelalisib in relapsed or refractory follicular lymphoma
2020-003695-40Phase 2Completed
- Sponsor
- ADC Therapeutics
- Start
- Mar 2021
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in follicular lymphoma (FL) comparing Loncastuximab tesirine with Idelalisib (2 arms). Primary endpoint: Complete response rate. Started Mar 2021; status: completed.
02
Drugs
loncastuximab tesirineidelalisib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2020-003695-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003695-40.